Vosoritide

Vosoritide (BMN 111) is a modified recombinant CNP (C-type natriuretic peptide) analogue, binds to NPR-B (natriuretic peptide receptor type B) and reduces the activity of FGFR3 (fibroblast growth factor receptor 3) . Vosoritide can be used in achondroplasia and dwarfism research[1][2][3].

Product Specifications

CAS Number

[1480724-61-5]

Product Name Alternative

BMN 111

UNSPSC

12352209

Target

FGFR

Type

Peptides

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/vosoritide.html

Purity

99.89

Solubility

H2O : 50 mg/mL

Smiles

O=C(NCC(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC1=CNC=N1)C(N2[C@@H](CCC2)C(N[C@@H](CC(N)=O)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CCCCN)C(NCC(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CSSC[C@@H](C(O)=O)NC4=O)C(N[C@@H](CC5=CC=CC=C5)C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@@H](C)CC)C(NCC(N[C@@H](CO)C(N[C@@H](CCSC)C(N[C@@H](CO)C(NCC(N[C@@H](CC(C)C)C(NC4)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]6NCCC6

Molecular Formula

C176H290N56O51S3

Molecular Weight

4102.73

References & Citations

[1]Duggan S. Vosoritide: First Approval. Drugs. 2021 Nov;81 (17) :2057-2062.|[2]Shuhaibar LC, et al. Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth. JCI Insight. 2021 May 10;6 (9) :e141426.|[3]Lorget F, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012 Dec 7;91 (6) :1108-14.